These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 39085100)

  • 1. Circadian Rhythms in Urology: Bridging Benign Prostatic Hyperplasia and Cardiovascular Disease Risk.
    Lin YH; Lin PT; Lin KJ
    Circ J; 2024 Aug; 88(9):1596. PubMed ID: 39085100
    [No Abstract]   [Full Text] [Related]  

  • 2. Circadian Rhythms in Urology: Bridging Benign Prostatic Hyperplasia and Cardiovascular Disease Risk　- Reply.
    Suzuki Y; Kaneko H; Morita H; Node K; Komuro I
    Circ J; 2024 Aug; 88(9):1597. PubMed ID: 39085098
    [No Abstract]   [Full Text] [Related]  

  • 3. Circadian rhythm of blood pressure in patients with benign prostatic hyperplasia.
    Turgut F; Bayrak O; Kanbay M; Ozkara A; Uz E; Bavbek N; Kargili A; Akcay A
    Scand J Urol Nephrol; 2008; 42(1):47-52. PubMed ID: 17853012
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The prevention and drug correction of cardiovascular changes in prostatic cancer patients].
    Gembitskiĭ EV; Begunov AV
    Voen Med Zh; 1994 Feb; (2):35-7. PubMed ID: 7513112
    [No Abstract]   [Full Text] [Related]  

  • 5. Night-time polyuria and nocturia.
    Matthiesen TB; Rittig S; Nørgaard JP; Pedersen EB; Djurhuus JC
    Scand J Urol Nephrol Suppl; 1995; 173():81-2. PubMed ID: 8719574
    [No Abstract]   [Full Text] [Related]  

  • 6. [Letter: Nycturia in prostatic hypertrophy].
    Sigel A
    Dtsch Med Wochenschr; 1974 Aug; 99(31):1606. PubMed ID: 4135678
    [No Abstract]   [Full Text] [Related]  

  • 7. Nocturia, aging, benign prostatic hypertrophy, and nocturnal vasopressin. A case report.
    Donahue JL; Weiner ID; Lowenthal DT
    Geriatr Nephrol Urol; 1997; 7(2):111-7. PubMed ID: 9422707
    [No Abstract]   [Full Text] [Related]  

  • 8. Benign prostatic hyperplasia and cardiovascular risk: a prospective study among Chinese men.
    Wang X; Su Y; Yang C; Hu Y; Dong JY
    World J Urol; 2022 Jan; 40(1):177-183. PubMed ID: 34426873
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Re: Shinbo et al.: Resistive index as risk factor for acute urinary retention in patients with benign prostatic hyperplasia (Urology 2010;76:1440-1445).
    Shenoy SP; Suvarna R; Marla PK
    Urology; 2011 May; 77(5):1268. PubMed ID: 21539979
    [No Abstract]   [Full Text] [Related]  

  • 10. [Correlation of the hourly and daily clearance in prostate adenoma].
    Mal'kov PS; Guseĭnov KhS
    Urol Nefrol (Mosk); 1979; (5):35-8. PubMed ID: 93822
    [No Abstract]   [Full Text] [Related]  

  • 11. [Benign prostatic hyperplasia and urolithiasis].
    Krombach P; Michel MS
    Urologe A; 2010 Sep; 49 Suppl 1():149-53. PubMed ID: 20812042
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Circadian rhythms in cardiovascular disease: the crucial hours.
    Detry JM; Vincent M
    J Hum Hypertens; 1992 Dec; 6 Suppl 1():S3-8. PubMed ID: 1293306
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiac Clocks and Preclinical Translation.
    Mistry P; Duong A; Kirshenbaum L; Martino TA
    Heart Fail Clin; 2017 Oct; 13(4):657-672. PubMed ID: 28865775
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Circadian rhythms and the heart: implications for chronotherapy of cardiovascular diseases.
    Manfredini R; Gallerani M; Salmi R; Fersini C
    Clin Pharmacol Ther; 1994 Sep; 56(3):244-7. PubMed ID: 7924118
    [No Abstract]   [Full Text] [Related]  

  • 15. [Clinical efficacy and safety of terazosine (setegis) in patients with benign prostatic hyperplasia with concomitant cardiovascular diseases].
    Trapeznikova MF; Gurevich MA; Pozdniakov KV; Tazina SIa; Bychkova NV
    Urologiia; 2005; (2):50-3. PubMed ID: 15989029
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Consequences of Circadian Disruption on Cardiometabolic Health.
    Reutrakul S; Knutson KL
    Sleep Med Clin; 2015 Dec; 10(4):455-68. PubMed ID: 26568122
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Evaluation of the effectiveness of prazosin in conservative treatment of benign prostatic hypertrophy].
    Górecki R; Krzeski T; Wasik J; Borówka A
    Pol Tyg Lek; 1992 Jun 15-29; 47(24-26):549-51. PubMed ID: 1282713
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Role of circadian rhythms and cellular clock in aging-related diseases].
    Panchenko AV; Gubareva EA; Anisimov VN
    Adv Gerontol; 2016; 29(3):417-423. PubMed ID: 28525688
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiovascular diseases: a therapeutic perspective around the clock.
    Soares AC; Fonseca DA
    Drug Discov Today; 2020 Jun; 25(6):1086-1098. PubMed ID: 32320853
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lower urinary tract symptoms/benign prostatic hypertrophy and vascular function: Role of the nitric oxide-phosphodiesterase type 5-cyclic guanosine 3',5'-monophosphate pathway.
    Higashi Y
    Int J Urol; 2017 Jun; 24(6):412-424. PubMed ID: 28332240
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.